GSK and Scynexis Ink Antifungal Licensing Deal Drug

GSK and Scynexis have inked a licensing deal giving GSK rights to commercialize Scynexis’s antifungal drug Brexafemme (ibrexafungerp) to reduce incidence of vulvovaginal candidiasis, also known as vaginal yeast infection.

Currently in phase 3 clinical trials, Brexafemme has broad spectrum activity and has potential as a treatment for other serious fungal infections.

The licensing deal also allows GSK rights to develop Brexafemme for treatment of patients with invasive candidiasis, a serious infection that can affect various parts of the body including the blood, heart, brain, eyes and bones.

Scynexis will receive an upfront payment of $90 million and potential milestone payments totaling $503 million.

Related Topics